Macaya Carlos, Moreno Raul
Cardiology Department , University Hospital Clinico San Carlos, Madrid, Spain.
Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):598-9. doi: 10.1038/ncpcardio1306. Epub 2008 Aug 5.
In the ABSORB trial, the feasibility of using a fully bioabsorbable everolimus-eluting stent (BVS; Abbott Vascular, Santa Clara, CA) in patients with ischemia and a single de novo coronary lesion was investigated. Some important concerns about the efficacy of this device were raised by this study. The in-stent late loss with the BVS (0.44 mm) was comparable to that seen with some drug-eluting stents currently on the market, and the late lumen loss was primarily due to reduction in stent area. Technical improvements aimed at definitively preventing late vessel recoil and negative remodeling, as well as clarification of the behavior of these devices with longer follow-up, are needed before fully bioabsorbable drug-eluting stents can be considered a therapeutic option for patients with coronary artery disease.
在ABSORB试验中，研究了使用完全可生物吸收的依维莫司洗脱支架（BVS；雅培血管公司，加利福尼亚州圣克拉拉）治疗有缺血症状和单一新发冠状动脉病变患者的可行性。该研究引发了对该装置疗效的一些重要担忧。BVS的支架内晚期管腔丢失（0.44毫米）与目前市场上一些药物洗脱支架的情况相当，晚期管腔丢失主要是由于支架面积缩小。在完全可生物吸收的药物洗脱支架被视为冠心病患者的一种治疗选择之前，需要进行旨在明确预防晚期血管回缩和负性重塑的技术改进，以及通过更长时间的随访来阐明这些装置的行为。
